| Name | diflomotecan |
|---|---|
| Synonyms |
diflomotecan
QKT1LC4J1P 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-, (5R)- 3H,15H-Oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-, (5R)- (5R)-5-Ethyl-9,10-difluoro-5-hydroxy-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione |
| Description | Diflomotecan (BN 80915) is a potent inhibitor of topoisomerase I. Diflomotecan causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds[1]. |
|---|---|
| Related Catalog | |
| Target |
topoisomerase I[1] |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 784.2±60.0 °C at 760 mmHg |
| Molecular Formula | C21H16F2N2O4 |
| Molecular Weight | 398.359 |
| Flash Point | 428.1±32.9 °C |
| Exact Mass | 398.107819 |
| LogP | 1.73 |
| Vapour Pressure | 0.0±2.9 mmHg at 25°C |
| Index of Refraction | 1.696 |